Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

enzalutamide 2radium Ra 223 dichloride 1poly ICLC 1olaparib 1fluciclovine F-18 1cabazitaxel 1bempegaldesleukin 1afuresertib 1Radiosurgery 1Radionuclide Imaging 1Prednisone 1Nivolumab 1Docetaxel 1Clinical Trials, Phase I as Topic 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-resistant Prostate Cancer × bempegaldesleukin × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡